Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
17/06/2026 06:04
BRIEF-UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics June 17 (Reuters) - Ucb SA UCB.BR:
COMPLETES ACQUISITION OF CANDID THERAPEUTICS
TOTAL TRANSACTION IS VALUED AT UP TO US $2.2 BILLION
UP TO US $200 MILLION IN POTENTIAL FUTURE MILESTONE PAYMENTS
CANDID'S INVESTIGATIONAL DRUG CIZUTAMIG HAS NOT BEEN APPROVED BY FDA OR OTHER HEALTH AUTHORITIES
Source text: ID:nNDL539wC8
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside